Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating:

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.